2022 Ljubljana, Slovenia

III-01 Noha Abdelgawad
Population Pharmacokinetic Modeling of Linezolid in Plasma and Cerebrospinal Fluid in Adults with Tuberculous Meningitis (LASER-TBM Study)
Thursday 09:50-11:20
III-02 Mahmoud Abdelwahab
Exposure-QTc modelling of Bedaquline, Clofazimine and Pretomanid in TB patients.
Thursday 09:50-11:20
III-03 Fauke Assmus
Pharmacokinetic-pharmacodynamic analysis of DNDi-6148 in pre-clinical models of visceral leishmaniasis
Thursday 09:50-11:20
III-04 Linda Aulin
The FAIR approach: Utilising a modelling and simulation workflow leveraging multisource data to support preclinical development and clinical trials
Thursday 09:50-11:20
III-05 Salma Bahnasawy
A pharmacometric model on cytokine changes upon live Escherichia coli exposure in a porcine sepsis model
Thursday 09:50-11:20
III-06 Enrique José Bandín Vilar
Correlation between trough concentrations and AUC of linezolid for sampling optimization in critically ill patients
Thursday 09:50-11:20
III-07 Muhammad Bilal
Cefepime Population Pharmacokinetics and Target Attainment in Critically ill Patients with Estimation of Probability of Neurotoxicity
Thursday 09:50-11:20
III-08 Davide Bindellini
Semi-mechanistic model-based analysis of plasma and target-site cefazolin pharmacokinetics and protein binding in obese and nonobese patients
Thursday 09:50-11:20
III-09 Dong Woo Chae
Dynamical modeling of phage therapy using in vitro and in vivo preclinical data
Thursday 09:50-11:20
III-10 Piyawat Chaivichacharn
Dose Reduction and Population Pharmacokinetics of Lopinavir/ritonavir with and without Rifampin in Thai HIV-infected patients
Thursday 09:50-11:20
III-11 Vincent Chang
Stratified medicine approaches for the treatment of drug-susceptible tuberculosis: a novel phase 2 trial design
Thursday 09:50-11:20
III-12 Lu Chen
An integrated population pharmacokinetic analysis for posaconazole oral suspension, delayed-release tablet, and intravenous infusion in healthy volunteers
Thursday 09:50-11:20
III-13 Wan-Yu Chu
Semi-mechanistic PK modelling of drug-macrophage interactions affecting the disposition of liposomal amphotericin B in plasma and skin tissue of post kala-azar dermal leishmaniasis patients
Thursday 09:50-11:20
III-15 Selma El Messaoudi
A semi-mechanistic model to characterize the long-term dynamic of HBV markers during treatment with lamivudine and PEG-IFNa
Thursday 09:50-11:20
III-16 Omar Elkayal
A patient-level population pharmacokinetics meta-analysis of three posaconazole formulations in immunocompromised paediatric patients
Thursday 09:50-11:20
III-17 Sandra Grañana Castillo
Physiologically based pharmacokinetic (PBPK) modelling of drug-drug interactions between long-acting cabotegravir and rilpivirine with oral rifabutin
Thursday 09:50-11:20
III-18 Silvia Grandoni
Antitubercular effects of TBAJ-587 a new diarylquinoline derivative on sub-populations of M. tuberculosis and prediction of early bactericidal activity in humans
Thursday 09:50-11:20
III-19 Yuchen Guo
Modeling spatial pharmacokinetics of drugs in mucus in patients with cystic fibrosis
Thursday 09:50-11:20
III-22 Sara Iannuzzi
Mathematical modelling of the molecular mechanisms of interaction of tenofovir with emtricitabine against HIV
Thursday 09:50-11:20
III-23 Anouk Jansen
Population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of an intravenous nanocrystal formulation
Thursday 09:50-11:20
III-25 Aida Kawuma
Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)
Thursday 09:50-11:20
III-26 Charlotte Kern
Development of a priori dosing nomograms for daptomycin in patients at Swiss university hospitals
Thursday 09:50-11:20
III-27 Christine Juliane Kleist
A PKPD model of ribavirin in Lassa virus infected mice
Thursday 09:50-11:20
III-28 Simon Koele
Power to characterize exposure-response relations in phase IIa tuberculosis (TB) trials using bacterial load modeling
Thursday 09:50-11:20
III-29 Daming Kong
A pooled pharmacokinetic analysis of piperacillin-tazobactam in different patient populations
Thursday 09:50-11:20
III-30 Niklas Kroemer
A general pharmacodynamic interaction modelling approach to assess semi-mechanistic synergy of ceftazidime/avibactam and fosfomycin in time kill experiments
Thursday 09:50-11:20
III-31 Max Lagraauw
Population Pharmacokinetic Analysis and Probability of Target Attainment Simulations of Pivmecillinam for the Treatment of Uncomplicated Urinary Tract Infection
Thursday 09:50-11:20
III-33 Letao Li
Model informed precision dosing of meropenem in critically ill patients: mission impossible?
Thursday 09:50-11:20
III-34 Guillaume Lingas
Modelling SARS-CoV-2 viral dynamics in hospitalized patients: implications for therapeutic evaluation
Thursday 09:50-11:20
III-36 Aurélien MARC
Characterization of SARS-CoV-2 variants of concern viral dynamics in non-human primates
Thursday 09:50-11:20
III-37 Huang Miao-Chan
Population pharmacokinetics of amoxicillin in postpartum minipig plasma
Thursday 09:50-11:20
III-38 Iris Minichmayr
Model-informed evaluation of prolonged versus short infusion regimens of meropenem based on two strategies of preclinical-clinical translation
Thursday 09:50-11:20
III-39 Nele Mueller-Plock
Predicting RSV Efficacy for MK-1654 During Post-COVID-19 Pandemic RSV Seasons with Protracted Transmission Pattern using MBMA and Clinical Trial Simulation Approaches that Account for RSV Force-of-Infection
Thursday 09:50-11:20
III-40 Glauco Nardotto
Population pharmacokinetics of rifampicin and 25-O-desacetyl-rifampicin in Brazilian patients with pulmonary tuberculosis living or not with HIV.
Thursday 09:50-11:20
III-41 Thi Lien Ngo
Development of a physiological-based pharmacokinetic model for tegoprazan: its application to prediction of drug-drug interactions with clarithromycin
Thursday 09:50-11:20
III-42 Amaury O'Jeanson
A simulation-based evaluation of the pharmacokinetic-pharmacodynamic (PK/PD) index approach for avibactam
Thursday 09:50-11:20
III-44 Yaru Peng
Population pharmacokinetic meta-analysis and dosing recommendation of meropenem in critically ill patients receiving continuous renal replacement therapy
Thursday 09:50-11:20
III-46 Juan Eduardo Resendiz Galvan
Population pharmacokinetics of moxifloxacin in Indian patients with multi-drug resistance tuberculosis
Thursday 09:50-11:20
III-47 Federico Romano
Extrapolation of the early bacterial activity of pretomanid to inform dose selection for the treatment of pulmonary tuberculosis
Thursday 09:50-11:20
III-48 Mohammed Saleh
Integration of the LeiCNS-PK3.0 PBPK framework and multiscale data to select anti-COVID19 drugs with favorable brain pharmacokinetics
Thursday 09:50-11:20
III-49 Louis Sandra
Development of an indirect response model-based meta-analysis framework for the analysis of viral antigen decline for RNA interference-based anti-hepatitis B therapies
Thursday 09:50-11:20
III-50 Maria Luisa Sardu
Establishing correlates of protection for herpes zoster infection via MBMA analysis
Thursday 09:50-11:20
III-51 Stef Schouwenburg
Oral versus intravenous amoxicillin in neonates: a population pharmacokinetic study
Thursday 09:50-11:20
III-52 Gianluca Selvaggio
A QSP model to inform dose decision and fast track candidate lead in mRNA vaccines development
Thursday 09:50-11:20
III-53 Jérémy Seurat
Rifampin co-administration with clindamycin can result in failure to reach the PKPD targets in staphylococcal osteoarticular infections
Thursday 09:50-11:20
III-54 Eva Sörensson
A pharmacokinetic-pharmacodynamic model characterizing antibiotic-induced morphological changes in Pseudomonas aeruginosa from time-lapse microscopy images
Thursday 09:50-11:20
III-55 Wisse van Os
Lefamulin exposure in soft tissues: population pharmacokinetics and pharmacokinetic/pharmacodynamic target attainment
Thursday 09:50-11:20
III-56 Luka Verrest
Paromomycin population pharmacokinetic analysis in Eastern African visceral leishmaniasis patients
Thursday 09:50-11:20
III-57 Umberto Villani
Probability of target attainment and dose optimisation of ceftriaxone in children and neonates
Thursday 09:50-11:20
III-58 Ella Widigson
A pharmacometric evaluation of atypical plasma protein binding and probability of target attainment of tigecycline in obese and nonobese patients
Thursday 09:50-11:20
III-59 Marie Wijk
Ethambutol population pharmacokinetics in South African patients with drug-susceptible tuberculosis
Thursday 09:50-11:20
III-60 Tan Zhang
Vancomycin clearance in obese adults is not predictive of clearance in obese adolescents
Thursday 09:50-11:20
III-61 Yuanxi Zou
Relative bioavailability of delamanid dispersed in water in healthy volunteers
Thursday 09:50-11:20